Hiroshi Higuchi is the managing partner of Allegro IP Law Firm. With more than 20 years of experience in the field of intellectual property law, Hiroshi handles patent and trademark matters in Japan for the most advanced companies and universities across the world. Before founding Allegro IP, Hiroshi was an attorney with Yanagida & Associates and served as the leader of the foreign clients team. Prior to joining the Yanagida firm, he was an in-house attorney with a Fortune Global 500 company and a US Patent Agent with a large boutique IP firm in DC area. He is qualified as a litigating attorney and received a bachelor’s degree from the University of Tokyo.
- Speaker | Recent changes in Japanese IP laws | MIPLA (Michigan Intellectual Property Law Association) luncheon seminar | Michigan, U.S.A. | November 2019
- Panelist | Practicing IP in Japan | University of Michigan Law School IPSA| Michigan, U.S.A. | November 2019
- Speaker | New ruling on protection of extended pharmaceutical patent rights in Japan| AIPLA Mid-Winter Institute IP Practice in Japan Committee Pre-meeting | Florida, U.S.A. | January 2019
- Protection of adidas Three-Stripes trademark protection in Japan | INTA | San Francisco, U.S.A. | May 2011
- Speaker | CAFC – Cordis Corp. v. Boston Scientific Corp. (Written Description)| JPAA International Activities Center | Tokyo, Japan | April 2011
- Speaker | IP High Court – Yokohama Rubber v. Yonex (Doctrine of Equivalents)| AIPLA Annual Meeting IP Practice in Japan Committee Pre-meeting | Washington D.C., U.S.A. | October 2009
- JPAA (Japan Patent Attorneys Association) (2005-)
– International Activities Center, JP Division | AIPLA PG | IPO PG, 2018-2021
– International Activities Center, EP Division, 2012
– International Activities Center, US Division, 2011
- JIPAC (Japan Intellectual Property Arbitration Center) – Mediator, Arbitrator & Panelist candidate, 2019-2022
- FICPI (International Federation Intellectual Property Attorneys)
- INTA (International Trademark Association)
- APAA (Asian Patent Attorneys Association)
Kaori Kohno brings an extensive technical background to her intellectual property law practice, focusing primarily on pharmaceuticals, biotechnology, and chemistry matters. She counsels clients on complex patent procurement matters. She has over 20 years of experience as a prosecutor before the Japan Patent Office. In addition to her prosecution experience, Kaori has developed vast experience in complex proceedings, such as appeals and oppositions. Before joining Allegro IP, she was an attorney with Yanagida & Associates. Prior to entering law practice, she served as a Pharmacist and a Radiation Protection Supervisor. She received a master’s degree from Kyoto University.
Tsuyoshi Sakuma is one of Japanese leading intellectual property experts. He has over 30 years of experience in handling patent matters in a wide variety of technologies including the electrical, mechanical, and software arts. He is also an expert in the fields of copyright, design and trademark matters. Tsuyoshi guides clients through complex procurement and litigation matters. Prior to entering legal practice, he was an engineer at the R&D division with a Fortune Global 500 company. He received a bachelor’s degree from Hiroshima University.
Reiko Hase has 15 years’ experience in trademark law. She kick-started her legal career as the in-house counsel at a multinational electronics company, then continued as the in-house counsel at what was then Japan’s largest pharmaceutical company. After joining a top Japanese patent law firm, Reiko managed some of the most distinguished trademark portfolios in Japan, also representing domestically world-famous brands from Italy, the UK, Switzerland, and the US.
With her wealth of experience as an in-house counsel, Reiko understands the specific needs of businesses and embraces with characteristic enthusiasm her current role as an outside counsel working with domestic and international companies alike to manage risk and offer cutting-edge, practical solutions. Reiko has represented many companies before the Japan Patent Office and the IP High Court.
In addition to manage the trademark portfolio of a top automobile manufacturer, Reiko guides leading Japanese companies in the food and chemical industries through complex trademark searches, prosecutions, negotiations, oppositions and invalidations.
- As the in-house counsel for multinational electronics company, Reiko successfully took down numerous counterfeits from auction sites.
- When negotiating on behalf of a top pharmaceutical company against a rival company, Reiko successfully resolved a potentially serious drug-safety issues and trademark opposition simultaneously.
- Reiko has managed the trademark portfolio of an industry-leading automobile manufacturer for over six years.
- JPAA (Japan Patent Attorneys Association)
- Japan Trademark Association
- INTA (International Trademark Association)
- JTA Bulletin Vol. 19 – Vol. 23
- Trademarks for Prescription Drugs (2016-2017)
Benjamin B. Lu, Ph.D.
Dr. Lu practice focuses on patent and trademark prosecution. He has prosecuted hundreds of biotechnology/pharma patent applications and trademark applications in the U.S. Prior to his legal career, Dr. Lu worked for more than a decade at large pharmaceutical companies including Pfizer, Monsanto, and Johnson & Johnson. Dr. Lu has extensive research and during his graduate study at UCLA, he authored dozens of scientific articles published in prestigious peer-reviewed journals, including Nature and Cell.
U.S. Patent and Trademark Office
- Lu, B., Sasai, Y., Piccolo, S., De Robertis, E.M. (1996) EMBO J. 15, 4547.
- Piccolo, S., Sasai, Y., Lu, B., De Robertis, E.M. (1996) Cell 86, 589.
- Sasai, Y., Lu, B., et al. (1995) Nature 378, 419.
- Holley, S.A., Jackson, P.D., Sasai, Y., Lu, B. et al. (1995) Nature 376, 249.
- Sasai, Y., Lu, B., Steinbeisser, H., De Robertis, E.M. (1995) Nature 376, 333.
- Sasai, Y., Lu, B.et al. (1994) Cell 79, 779.
Takahisa Murata, DVM, Ph.D.
- L-PGDS-derived PGD2 attenuates acute lung injury by enhancing endothelial barrier formation | Horikami, D., Toya, N., Kobayashi, K., (…), Nagata, N., Murata, T. | Journal of Pathology, 2019
- Hematopoietic prostaglandin D synthase-derived prostaglandin D2 ameliorates adjuvant-induced joint inflammation in mice | Tsubosaka, Y., Maehara, T., Imai, D., (…), Fujii, W., Murata, T. | FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2019
- Therapeutic potential of D prostanoid receptor 1 signal enhancement in a murine model of food allergy | Nakamura, T., Hirai, R., Tachibana, Y., (…), Nagata, N., Murata, T. | Journal of Allergy and Clinical Immunology, 2019
- Comparison of urine and blood as a convenient and practical sample for estimating the contamination level of live cattle with radioactive cesium | Sato, I., Sasaki, J., Satoh, H., (…), Murata, T., Okada, K | Animal Science Journal, 2019
- Production of lipid mediators in mastitic milk of cow | Hayashi, A., Fujii, S., Nakamura, T., (…), Takahashi, T., Murata, T. | Animal Science Journal, 2019
- Mast cell-derived PGD2 attenuates anaphylactic reactions in mice. Nakamura T, Fujiwara Y, Yamada R, Fujii W, Hamabata T, Lee MY, Maeda S, Aritake K, Roers A, Sessa WC, Nakamura M, Urade Y, *Murata T.J Allergy Clinical Immunology.2017, in press.
- PGD2 deficiency exacerbates food antigen-induced mast cell hyperplasia. Nakamura T, Maeda S, Horiguchi K, Maehara T, Aritake K, Choi B, Iwakura Y, Urade Y, *Murata T. Nature Communications. 6:7514 2015.
- Iwanaga K, Nakamura T, Maeda S, Aritake K, Hori M, Urade Y, Ozaki H, *Murata T. Mast Cell-Derived Prostaglandin D2 Inhibits Colitis and Colitis-Associated Colon Cancer in Mice. Cancer Res. 74(11):3011-9. 2014.
- *Murata T, Aritake K, Tsubosaka Y, Maruyama T, Nakagawa T, Hori M, Hirai H, Nakamura M, Narumiya S, Urade Y, Ozaki H. Anti-inflammatory role of PGD2 in acute lung inflammation and therapeutic application of its signal enhancement. Proc Natl Acad Sci U S A. 26;110(13):5205-10.2013.
- eNOS derived nitric oxide regulates endothelial barrier function via VE cadherin and Rho GTPases. DiLorenzo A, Lin M, Murata T, Landskroner-Eiger S, Schleicher M, Kothiya M, Iwakiri Y, Yu J, Huang P, *Sessa WC. Journal of Cell Science. 126(Pt 24):5541-52. 2013.
- *Murata T, Aritake K, Matsumoto S, Kamauchi S, Nakagawa T, Hori M, Momotani E, Urade Y, Ozaki H. Prostagladin D2 is a mast cell-derived antiangiogenic factor in lung carcinoma. Proc Natl Acad Sci U S A 108(49):19802-7. 2011.
- SHIMADZU Global Innovation Summit Award, A Novel Biomarker of Food Allergy, 2017
- The Japanese Vascular Biology and Medicine Organization, Young Investigator Highest Award, Development of a vascularization promoting agent, 2016
- Japanese Cancer Association, Incentive Award, Discovery of a molecule inhibiting the development and progression of cancer and therapeutic application thereof, 2016
- The Japanese Vascular Biology and Medicine Organization, Young Investigator Award, Mast cell-derived PGD2 inhibits neoangiogenesis in lung carcinoma, 2011